Eton Pharmaceuticals, Inc.
ETON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $39,011 | $31,642 | $21,251 | $21,832 |
| % Growth | 23.3% | 48.9% | -2.7% | – |
| Cost of Goods Sold | $15,600 | $10,581 | $6,933 | $2,623 |
| Gross Profit | $23,411 | $21,061 | $14,318 | $19,209 |
| % Margin | 60% | 66.6% | 67.4% | 88% |
| R&D Expenses | $3,255 | $3,322 | $3,996 | $6,235 |
| G&A Expenses | $22,753 | $18,931 | $18,582 | $14,469 |
| SG&A Expenses | $22,753 | $18,931 | $18,582 | $14,469 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26,008 | $22,253 | $22,578 | $20,704 |
| Operating Income | -$2,597 | -$1,192 | -$8,260 | -$1,495 |
| % Margin | -6.7% | -3.8% | -38.9% | -6.8% |
| Other Income/Exp. Net | -$1,211 | $503 | -$761 | -$460 |
| Pre-Tax Income | -$3,808 | -$689 | -$9,021 | -$1,955 |
| Tax Expense | $15 | $247 | $0 | $0 |
| Net Income | -$3,823 | -$936 | -$9,021 | -$1,955 |
| % Margin | -9.8% | -3% | -42.4% | -9% |
| EPS | -0.15 | -0.037 | -0.36 | -0.078 |
| % Growth | -311% | 89.9% | -363.9% | – |
| EPS Diluted | -0.15 | -0.037 | -0.36 | -0.078 |
| Weighted Avg Shares Out | 25,895 | 25,645 | 25,146 | 25,207 |
| Weighted Avg Shares Out Dil | 25,895 | 25,645 | 25,146 | 25,207 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2,005 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,146 | $901 | $1,774 | $462 |
| EBITDA | -$1,451 | -$291 | -$6,486 | -$1,033 |
| % Margin | -3.7% | -0.9% | -30.5% | -4.7% |